PeerVoice

cme oncology general practice primary care covid-19 vaccination covid vaccination covid-19 covid adcs breast cancer nsclc sars-cov-2 adc type 2 diabetes infectious diseases ce next-generation sequencing hfref heart failure with reduced ejection fraction hf immunohistochemistry ckd infectious disease pembrolizumab ngs genetic testing ondemand diabetes antibody drug conjugates antibody drug conjugate mtnbc tnbc trastuzumab deruxtecan her2 ihc her3 cholangiocarcinoma chemotherapy antiretroviral therapy cisplatin hba1c cca metastatic triple negative breast cancer triple negative breast cancer neurology cardiology heart failure chronic kidney disease t2dm egfr mcrc metastatic colorectal cancer screening urology psma pet combination therapy stigma art people living with hiv plwh hiv panel neuropathy met overexpression met amplification lung cancer antibody-drug conjugates orr adc interstitial lung disease adc vomiting adc nausea adc diarrhoea adc neutropenia adc side effects adc toxicity adc safety fluorescence in situ hybridization fish neuromuscular junction gmg generalised myasthenia gravis myasthenia gravis nephrology angiotensin receptor neprilysin inhibitor arni arb overall survival os metastatic non-small cell lung cancer mra crc advanced colorectal cancer colorectal cancer nirmatrelvir/ritonavir covid-19 treatment covid treatment covid-19 testing covid testing immunotherapy met fusion chronic obstructive pulmonary disease copd echo echocardiography multimodal imaging multidisciplinary care cardiomyopathy mindset perry elliott cardiac myosin inhibitor septal reduction cascade testing left ventricular ejection fraction lvef left ventricular outflow tract obstruction lvoto esc guidelines hcm hypertrophic cardiomyopathy guideline recommendations relapsing chronic nuclear medicine vision study vision trial radiopharmaceuticals lutetium dotatate lutetium psma 177-lutetium-psma-617 psma lutetium rlt radioligand therapy metastatic castration-resistant prostate cancer prostate cancer mcrpc nivolumab tyrosine kinase inhibitors sacituzumab govitecan datopotamab deruxtecan trop2 sleep disturbance psychological wellbeing emotional impact physical discomfort skin damage debilitating embarrassment lack of sleep fatigue pain bugs under my skin severe itch itch cholestatic pruritus pbc primary biliary cholangitis waist circumference bmi body mass index obesity treatment hcc hepatocellular carcinoma inhibitor icca intrahepatic metformin safety efficacy peer-to-peer molecular testing antibody-drug conjugate sensory loss small-fiber small fibre neuropathic pain attrv ttr transthyretin attr-pn attr–polyneuropathy attr transthyretin amyloidosis avelumab tki multidisciplinary pardeep s jhund david cherney sarah jarvis hematology haematology immunology allergy fda futibatinib actionable complement inhibitors c5 inhibitor ravulizumab eculizumab gastroenterology ras epidermal growth factor receptor testing covid myocarditis covid vaccines and myocarditis mrna vaccines in children mrna vaccines covid-19 vaccines in children covid vaccines in children covid-19 vaccines covid vaccines covid-19 vaccine covid vaccine disease scchn egfr-mutation mabs bispecific monoclonal antibodies tkis met exon 14 skipping met alterations bruton’s tyrosine kinase btk gilteritinib quizartinib sorafenib midostaurin flt3-tkd flt3 tyrosine kinase domain flt3-itd flt3 internal tandem duplication flt3 mutation lacewing trial ratify trial quantum-first trial admiral trial flt3-mutated aml flt3 inhibitors acute myeloid leukemia acute myeloid leukaemia aml ev-302 platinum-based chemotherapy enfortumab vedotin atezolizumab gem-cis carboplatin cancer thomas powles genitourinary oncology maintenance therapy locally urothelial carcinoma advanced urothelial carcinoma urothelial carcinoma barbara burtness md lisa licitra md fosaprepitant aprepitant gabapentin dexamethasone mannitol radiation-induced skin toxicity chemoradiotherapy-associated skin toxicities chemoradiotherapy-associated mucositis chemoradiotherapy-associated dehydration chemoradiotherapy side effects chemoradiotherapy toxicities chemoradiotherapy head and neck cancer squamous cell carcinoma of the head and neck sglt2 inhibitor acei four pillars raas inhibition renin-angiotensin-aldosterone system antoni bayés-genís alexandre mebazaa michael böhm javed butler gdmt guideline-directed medical therapy complement inhibition neonatal fc receptor fcrn inhibition acetylcholine receptor antibody acetylcholine receptor acetylcholine musk muscle-specific kinase generalized myasthenia gravis allogeneic stem cell transplantation hb plt anc absolute neutrophil count hemoglobin platelet count cytopenia marrow blast prognostic scoring ipss-r revised international prognostic scoring system hr-mds high-risk mds ipss-m molecular international prognostic scoring system myelodysplastic syndromes mds fresco-2 trial sunlight study sunlight trial mcrc treatment sequencing advanced crc treatment sequencing advanced crc vaccination elena arbelo dato-dxd communication psmafore study psmafore trial radioligand therapy patient selection andreas kremer md phd mhba device her2-low autonomic testing autonomic symptoms distal proximal lucia galán davila laura obici esmo pwo people with obesity adipose tenofovir alafenamide tenofovir disoproxil fumarate treatment of hiv hbv coinfection management of hiv hbv coinfection hiv and hbv coinfection hiv and hepatitis b coinfection hiv hbv coinfection hiv/hbv coinfection hbv hepatitis b virus biomarker replay bendamustine and rituximab polatuzumab vedotin car t car t-cell therapy response progression-free survival pfs survival asct scholar-1 ineligible sct stem cell transplant r/r dlbcl dlbcl relapsed/refractory diffuse large b-cell lymphoma hiv virologic failure charles w. flexner md antonella castagna md pi protease inhibitor viral load lenacapavir fostemsavir ibalizumab heavily treatment experienced highly treatment experienced mdr hiv multidrug-resistant hiv biliary tract cancer mutation idh1 positive alteration fusion cardiorenal risk glucose control treatment costs linong ji melanie j. davies established medication haemoglobin holistic patient-centred patient-centered cost effectiveness practical strategies heart failure chronic kidney disease general practitioner nephrologist cardiologist durvalumab aav gene therapy aav adeno-associated virus limb-girdle muscular dystrophy clinical trials limb girdle muscular dystrophy clinical trials clinical trials for lgmd lgmd clinical trials dysferlinopathy sarcoglycans limb-girdle genetic testing limb girdle genetic testing muscular dystrophy genetic testing genetic testing for lgmd lgmd genetic testing lgmd limb-girdle muscular dystrophy limb girdle muscular dystrophy muscular dystrophy herpes melanoma resistance non-small-cell lung cancer chicago dermatology objective response rate european medicines agency ema infigratinib pemigatinib fgfr human epidermal growth factor receptor 2 champion-mg trial champion-mg study raise study raise trial regain study regain trial zilucoplan nicholas j silvestri md ali a habib md james f howard jr md complement mediated attack angiotensin receptor blocker angiotensin-converting enzyme ace therapy raasi renin-angiotensin-aldosterone system inhibitor hyperkalaemia mace major adverse cardiovascular event antibodies expression uacr albuminuria cardiorenal cardiovascular outcomes renal outcomes eplerenone spironolactone finerenone mineralocorticoid receptor antagonist nonsteroidal mra braf esmo crc guidelines ctdna testing bevacizumab tas-102 tipiracil trifluridine regorafenib chiara cremolini md phd metastatic crc childbearing pregnancy covid antiviral andrew ustianowski mbbs frcp phd remdesivir molnupiravir sotrovimab covid-19 self testing covid self testing pinetree study pinetree trial comet-ice study comet-ice trial move-out study move-out trial epic-hr study epic-hr trial covid-19 self-testing covid self-testing long covid and qol long covid and quality of life covid-19 organ impairment covid organ impairment coverscan trial coverscan study covid multiorgan damage covid organ damage covid-19 multiorgan damage covid-19 organ damage long covid symptoms long covid risk long covid c. buddy creech md mph patient fscig immunoglobulin ici kevin harrington gadolinium opera ii opera i ocrelizumab remyelination neurodegeneration smouldering progression independent of relapse activity pira progression inflammation dmt disease-modifying treatment ms multiple sclerosis us food and drug administration bcr b cell receptor approval pirtobrutinib zanubrutinib acalabrutinib ibrutinib r/r relapsed/refractory tn treatment-naïve cll chronic lymphocytic leukaemia tropion-breast01 trial tropics-02 trial ascent trial trop2 therapy trop2-directed therapy in hr+/her2- breast cancer trop2-directed therapy hr-positive her2-negative advanced breast cancer h hr-positive advanced breast cancer hr+/her2- advanced breast cancer hr+ advanced breast cancer advanced breast cancer case vignettes hyperglycaemic hyperosmolar syndrome hhs glp-1 ra therapy episodes international society for pediatric and adolescent ispad dulaglutide exenatide liraglutide timothy barrett maria craig childhood diabetes type 2 diabetes in children and adolescents t2d ldh lactate dehydrogenase reticulocyte count pegcetacoplan proximal complement inhibitors terminal complement inhibitors haemolytic anaemia c3 inhibitor jeffrey szer ivh intravascular haemolysis bth breakthrough haemolysis evh extravascular haemolysis paroxysmal nocturnal haemoglobinuria pnh fetal antigen rhd immunoprophylaxis baby mother rh rh-negative rh-positive rbc red blood cell igg prophylaxis prevention pathophysiology hdfn haemolytic disease of the fetus and newborn ckd in t2dm jennifer green fatos pinar topsever microsatellite instability mismatch repair msi mmr anti-braf therapy anti-egfr therapy primary tumour location molecular status nicola normanno md dirk arnold md il-6 receptor inhibitors for myasthenia gravis complement inhibitors for myasthenia gravis complement inhibitors for gmg fcrn inhibitors targeted therapies for generalised myasthenia grav targeted therapies for gmg egfr tki ctdna circulating tumor dna amplicon hybrid capture polysomy met exon 14 skipping mutation met mutation met vulnerabilities met alteration radioligand therapy administration multidisciplinary management of mcrpc multidisciplinary management of radioligand therap 177-lutetium-pnt global initiative for chronic obstructive lung dis gold dual therapy inhaler inhaled corticosteroids long-acting muscarinic antagonist long-acting beta2 agonist ics lama laba ethos impact triple therapy non-pharmacologic pharmacologic intervention treatable traits myasthenia gravis autoantibodies postsynaptic membrane in myasthenia gravis titan receptor ryanodine receptor myasthenia gravis pathogenesis myasthenia gravis pathophysiology autoantibodies and myasthenia gravis sunlight trial efficacy sunlight study efficacy sunlight trial safety sunlight study safety advanced crc second-line treatment advanced crc fourth-line treatment advanced crc third-line treatment endocrinology gili regev-yochay md george kassianos cbe md (hons) frcgp covid revaccination covid bivalent vaccine covid monovalent vaccine covid vaccination recommendations xbb.1.5 xbb.1.5 vaccine sars-cov-2 virus tucatinib trastuzumab dustin deming md tanios bekaii-saab md marwan fakih md fresco-2 study influenza pertussis rsv respiratory syncytial virus comorbidities guidelines late intervention late diagnosis quality of life alpha-1 antitrypsin deficiency lung development childhood air pollution occupational exposure causes cessation smoking adverse event trophoblast cell surface antigen 2 triple-negative breast cancer low negative her2-negative hr+ hr-positive hormone receptor directed advise assess ask 5as whr ratio waist-to-hip weight bias neurobehavioural tongue fasciculation poor muscle tone congenital myopathy newborns newborn screening poor head control reduced reflexes delayed motor milestones neurological testing referral floppy baby sma spinal muscular atrophy neuromuscular disorders giovanni baranello laurent servais hypotonia 177-lutetium-pnt2002 boreas study boreas trial terranova study terranova trial galathea study galathea trial metreo study metreo trial metrex study metrex trial eclipse study eclipse trial copd endotypes unmet needs in copd type 2 inflammation airway inflammation respirology pulmonology cardiac magnetic resonance healthcare provider management barrier visceral diagnosis world health organization who obese pd-l1 score evoke-02 tropion-lung01 advanced nsclc melissa johnson edward b. garon actionable genomic alterations bdt biliary duct cancer collaboration mdt multidisciplinary team targeted test ecca extrahepatic psmafore rpfs mucocutaneous manifestations active skin disease sledai eular 2023 recommendations sle disease activity index treat-to-target approach treat to target biologicals biologic therapy belimumab anifrolumab corticosteroids hydroxychloroquine skin involvement skin flare rheumatology eular systemic lupus erythematosus sle ronald van vollenhoven ipilimumab sunitinib vincent xu md wenxin xu md brian i. rini md io immuno-oncology kidney cancer clear cell renal cell carcinoma clear cell rcc advanced renal cell carcinoma advanced rcc rcc renal cell carcinoma facilitated subcutaneous immunoglobulin artificial intelligence ai digital technologies technology dorothea grosse-kreul nicholas l. rider martin van hagen chronic disease ipic ig therapy immunoglobulin therapy trop2 adc trop-2 adc trop-2 new data on adcs prostate-specific membrane antigen positron emissi adt androgen deprivation therapy alicia k. morgans madrid christian gratzke karim fizazi nmcrpc mhspc nonmetastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer arpi androgen receptor pathway inhibitor androgen receptor pathway inhibition foetal considerations long-acting injectable therapy viral suppression life journey cognitive considerations ageing menopause reproductive considerations living with hiv susan cole justyna kowalska karoline aebi-popp sharon walmsley eacs warsaw andreas kremer carel le roux paolo sbraccia adiposity-based chronic disease treatable specific cardiovascular complications pillars of management chronic condition easd btc plan individualise personalise outcomes deletion insertion molecular profiling advanced tremelimumab immune checkpoint inhibitors immune checkpoint inhibitor io/io combinations advanced hepatocellular carcinoma advanced hcc pd-l1 pathway pd-1 pathway pd-l1 pd-1 ctla-4 targeted therapies ctla-4 targeted therapy anti-ctla-4 antibodies ctla-4 tusamitamab tissue rebiopsy multidisciplinary panel discussion maytansinoid keith m. kerr david planchard ceacam5-directed therapies ceacam5 expression carmen-lc06 carmen-lc05 carmen-lc04 carmen-lc03 carcinoembryonic antigen-related cell adhesion mol balazs halmos wong seng weng wclc 2023 wclc symposium solange peters singapore progressive lung cancer pasi jänne iaslc egfr-mutated egfr-mutant driver mutation systemic mastocytosis symptoms systemic mastocytosis symptom burden systemic mastocytosis smouldering systemic mastocytosis mastocytosis diagnostic criteria mastocytosis diagnosis mastocytosis mast cell kit mutation kit d816v mutation kit d816v indolent systemic mastocytosis frank siebenhaar md darier’s sign advanced systemic mastocytosis second-line rearrangement ntrk fgfr2 kdigo proteinuria upc urine protein-to-creatinine ratio irbesartan protect nefigard budesonide sparsentan clinical trials glomerular disease fsgs focal segmental glomerulosclerosis igan immunoglobulin a nephropathy ladan zand jai radhakrishnan panel discussion foenix-cca2 tas-120 checkpoint inhibitor gemcitabine liver metastases liver bile duct cancer nicola normanno angela lamarca arndt vogel esmo gi injection site -80o c approved node lymph t-vec talimogene laherparepvec dressing storage virus injection skin cancer oncolytic rp1 cemiplimab clinical benefit rate cbr her3-targeted american society of clinical oncology 2023 asco her3-dxd patritumab deruxtecan katrin hahn isabel conceição p. james b. dyck congress pns copenhagen cv-bond bond nocturnal dipping hypocretins circadian sleep-wake cycle orexin american heart association aha eds excessive daytime sleepiness cardiovascular sodium intake narcolepsy richard k. bogan phyllis c. zee michael thorpy indianapolis sleep 2023 keynote-412 chemoradiation xevinapant javelin head and neck 100 oropharyngeal cancer opc hpv-positive oropharyngeal cancer hpv human papillomavirus barbara burtness ezra cohen crt chemoradiation-eligible la scchn locally advanced squamous cell carcinoma of head a teliso-v telisotuzumab vedotin tepotinib capmatinib exon 14 skipping mutation edgardo s. santos jonathan goldman d. ross camidge c-met cmet met macroalbuminuria prediabetes patient journey sorena kiani mbphd frcp frcpath berotralstat lanadelumab icatibant attenuated androgen prophylaxis kallikrein-kinin pathway bradykinin attenuated androgens hereditary angioedema prophylaxis hae prophylaxis hae hereditary angioedema angioedema destiny-breast03 pneumonitis t-dm1 t-dxd trastuzumab duocarmazine trastuzumab emtansine her2-targeted antibody-drug conjugates her2-targeted adcs her2-targeted therapy and interstitial lung diseas her2-targeted therapy and ild drug-induced ild drug-induced interstitial lung disease ild interstitial lung disease her2-positive breast cancer committee for medicinal products for human use chmp united states food and drug administration fusions alterations fibroblast growth factor receptor her-targeted trial study toga her2-positive egfr; epidermal growth factor receptor mutations molecular alterations gej gastric cancer gastroesophageal junction cancer destiny-gastric02 trial glow study glow trial spotlight study spotlight trial rationale-305 study rationale-305 trial keynote-859 study keynote-859 trial checkmate 649 study checkmate 649 trial kohei shitara md nick pavlakis mbbs pld advanced gastric and esophageal cancer advanced gastric and oesophageal cancer esophageal cancer oesophageal cancer gastric cancer antibody target solid tumour heregulin hrg human epidermal growth factor 3 end-stage renal disease eskd esrd encorafenib circulating tumour dna tanios bekaii-saab john strickler md gerald prager md aasld hepatitis c positivity universal screening risk factors idu injection drug use age prevalence infection adolescents children pregnant women women hcv hepatitis c virus hepatitis c covid-19 vaccination in children covid vaccination in children home cvid common variable immunodeficiency nurse inflammatory administration infusion facilitated ivig intravenous scig subcutaneous primary immunodeficiencies immunodeficiency ig cetuximab extreme keynote-048 cps >20 cps <1 cps 1-19 jean-pascal machiels robert i. haddad r/m scchn recurrent/metastatic cps combined positive score squamous cell carcinoma of head and neck